These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2106677)

  • 1. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.
    Brazzell RK; Wooldridge CB; Hackett RB; McCue BA
    Pharm Res; 1990 Feb; 7(2):192-8. PubMed ID: 2106677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.
    Brazzell RK; Mayer PR; Dobbs R; McNamara PJ; Teng RL; Slattery JT
    Pharm Res; 1991 Jan; 8(1):112-8. PubMed ID: 1901647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saturable tissue binding and imirestat pharmacokinetics in rats.
    Chien JY; Banfield CR; Brazzell RK; Mayer PR; Slattery JT
    Pharm Res; 1992 Apr; 9(4):469-73. PubMed ID: 1495891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma.
    McCue BA; Park YH; Brazzell RK; Boltralik JJ
    J Chromatogr; 1991 Apr; 565(1-2):255-64. PubMed ID: 1908477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of the aldose reductase inhibitor AL01576 in rats.
    Park YH; Wooldridge CB; Mattern J; Stoltz ML; Brazzell RK
    J Pharm Sci; 1988 Feb; 77(2):110-5. PubMed ID: 3129545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.
    Hockwin O; Müller P; Krolczyk J; McCue BA; Mayer PR
    Ophthalmic Res; 1989; 21(4):285-91. PubMed ID: 2511536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits.
    Vaidyanathan G; Jay M; Bera RK; Mayer PR; Brazzell RK
    Pharm Res; 1990 Nov; 7(11):1198-200. PubMed ID: 2127314
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.
    Sunkara G; Ayalasomayajula SP; Rao CS; Vennerstrom JL; DeRuiter J; Kompella UB
    J Pharm Pharmacol; 2004 Mar; 56(3):351-8. PubMed ID: 15025860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation.
    Ohashi Y; Awata T; Sogo S; Ohira M; Matsuda M; Fukuda M; Manabe R
    J Ocul Pharmacol; 1989; 5(4):325-8. PubMed ID: 2516866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic assay of the aldose reductase inhibitor spiro-(2-fluoro-9H-fluorene-9,4'-imidazolidine)-2',5'-dione (AL01567) in plasma and urine and its pharmacokinetics in humans.
    Park YH; McCue BA; Dobbs RE; York BM; Brazzell RK
    J Pharm Sci; 1988 Jul; 77(7):591-5. PubMed ID: 3139862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
    Brazzell RK; Park YH; Wooldridge CB; McCue B; Barker R; Couch R; York B
    Drug Metab Dispos; 1990; 18(4):435-40. PubMed ID: 1976064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
    Kador PF; Randazzo J; Babb T; Koushik K; Takamura Y; Zhu W; Blessing K; Kompella UB
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):116-23. PubMed ID: 17444799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
    Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
    J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
    Sastry SG; Sanders RA; Veltman JC; Watkins JB
    Drug Metab Dispos; 1995 Oct; 23(10):1094-8. PubMed ID: 8654197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.
    Acheampong AA; Shackleton M; Tang-Liu DD; Ding S; Stern ME; Decker R
    Curr Eye Res; 1999 Feb; 18(2):91-103. PubMed ID: 10223652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
    Park YH; Barker R; Griffin B; Barratt D; DuPriest M; Brazzell K; York B; Mayer P
    Xenobiotica; 1992 May; 22(5):543-50. PubMed ID: 1413869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal permeability of aldose reductase inhibitor, M79175. II. In vivo study on pharmacokinetic aspect.
    Kato A; Horie T; Ishibashi Y; Miyake Y; Iwata S
    J Ocul Pharmacol; 1986; 2(3):287-94. PubMed ID: 3139809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).
    Park YH; Mayer PR; Barker R; DuPriest M; Griffin BW; Williams GW; York BM; Slattery JT
    Pharm Res; 1993 Apr; 10(4):593-7. PubMed ID: 8483844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Pharmacokinetic Evaluation of High Melanin Binder Levofloxacin in Rabbits Shows Potential of Topical Eye Drops for Posterior Segment Treatment.
    Bahrpeyma S; Jakubiak P; Alvarez-Sánchez R; Caruso A; Leuthardt M; Senn C; Del Amo EM; Urtti A
    Invest Ophthalmol Vis Sci; 2024 Oct; 65(12):14. PubMed ID: 39382881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
    Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.